keyword
MENU ▼
Read by QxMD icon Read
search

prophylaxis hematology

keyword
https://www.readbyqxmd.com/read/27905682/a-survey-of-pediatric-hematology-oncology-specialists-regarding-management-of-central-line-associated-venous-thrombosis
#1
Char M Witmer, Emily Sauck, Leslie J Raffini
Central venous catheters (CVCs) account for the largest proportion of thrombotic events in pediatric patients. Questions remain regarding adequate treatment and prevention methods. We surveyed pediatric hematology/oncology specialists, using hypothetical cases to assess management strategies for acute CVC thrombosis and secondary prevention. Survey respondents varied in the use of the thrombophilia evaluation (33.3%, 41/123) and duration of treatment (6 weeks: 54.1%, 66/122). Secondary CVC prophylaxis was utilized by 36...
December 1, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27905258/hla-mismatched-haploidentical-transplantation-using-low-dose-anti-thymocyte-globulin-atg-thymoglobulin
#2
Shinichi Kako, Yu Akahoshi, Naonori Harada, Hirofumi Nakano, Kazuaki Kameda, Tomotaka Ugai, Ryoko Yamasaki, Hidenori Wada, Yuko Ishihara, Koji Kawamura, Kana Sakamoto, Miki Sato, Masahiro Ashizawa, Kiriko Terasako-Saito, Shun-Ichi Kimura, Misato Kikuchi, Hideki Nakasone, Rie Yamazaki, Junya Kanda, Yoshinobu Kanda
Objectives To clarify optimal strategies for human leukocyte antigen (HLA)-mismatched haploidentical hematopoietic stem cell transplantation (HSCT). Methods Twelve patients who underwent HSCT from a haploidentical related donor using low-dose thymoglobulin were analyzed retrospectively. Thymoglobulin was added to conditioning regimens at 2.5 mg/kg/day for 2 days (days -4 and -3). Prophylaxis against graft-versus-host disease (GVHD) was performed with cyclosporine and methotrexate. Results The median age of the patients was 33 years...
December 1, 2016: Hematology (Amsterdam, Netherlands)
https://www.readbyqxmd.com/read/27904061/diagnosis-and-treatment-of-mucormycosis-in-patients-with-hematological-malignancies
#3
Yuki Asano-Mori
The risk of invasive fungal infections (IFIs) is extremely high in patients with hematological malignancies due to the prolonged and profound neutropenia and immunosuppression after chemotherapy and hematopoietic stem cell transplantation. There has been increasing interest in mucormycosis despite its relatively uncommon occurrence, because occasional breakthrough infections have been observed under anti-aspergillus prophylaxis. The aggressive nature of mucormycosis easily leads to high mortality because of delays in diagnosis and incorrect treatment decisions, which are due in part to lack of adjunctive diagnostic tools and having similar clinical and radiological features with aspergillosis...
2016: Medical Mycology Journal
https://www.readbyqxmd.com/read/27903025/-antifungal-medication-new-substances-new-experiences
#4
Dieter Buchheidt, Wolf-Karsten Hofmann
The incidence of life threatening invasive fungal infections in patients with hematological malignancies during intensive chemotherapy or after hematopoetic stem cell transplantation, patients after solid organ transplantation, ICU patients and premature infants is rising. Mortality rates of invasive fungal infections, caused by Aspergillus species or mucormycetes, may reach 100%, in spite of considerable progress in diagnosis, antifungal prophylaxis and therapy. Comprehensive, profound knowledge of specific diagnostic and current treatment algorithms is essential to improve the prognosis of patients suffering from systemic fungal infections; this article encompasses recent developments in the field of antifungal treatment...
November 2016: Deutsche Medizinische Wochenschrift
https://www.readbyqxmd.com/read/27899262/reactivation-of-hepatitis-b-virus-in-cancer-patients-treated-with-chemotherapy-for-solid-tumors-is-the-prophylaxis-really-required
#5
Alessandro Federico, Giuseppina Brancaccio, Marcello Dallio, Patrizia Iodice, Alessio Fabozzi, Salvatore Del Prete, Fortunato Ciardiello, Carmela Loguercio, Giovanni Battista Gaeta
BACKGROUND: Reactivation of hepatitis B virus during cancer chemotherapy for non-hematological tumors is not fully clear. AIM: To evaluate the risk of hepatitis B virus reactivation in carriers of hepatitis B virus cancer patients treated with chemotherapy for solid tumors. METHODS: Two hundred sixty-seven patients with solid tumors were consecutively enrolled: 13 (4.8%) were hepatitis B s-antigen positive, of whom 6 were documented inactive carriers and 7 had chronic liver disease...
November 16, 2016: Digestive and Liver Disease
https://www.readbyqxmd.com/read/27863665/biodegradable-hydrophilic-carriers-for-the-oral-delivery-of-hematological-factor-ix-for-hemophilia-b-treatment
#6
Sarena D Horava, Katie J Moy, Nicholas A Peppas
Current protein replacement therapies for hemophilia B, a genetic bleeding disorder caused by a deficiency in coagulation factor IX, rely on IV injections and infusions. Oral delivery of factor IX is a desirable needle-free option, especially for prophylaxis. We have developed a biodegradable, pH-responsive hydrogel microcarrier system based on the poly(methacrylic acid)-grafted-poly(ethylene glycol) [P(MAA-g-EG)]. Incorporation of an enzymatically degradable peptide crosslinking agent allows for site-specific degradation by trypsin in the small intestine...
November 30, 2016: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/27797367/serum-galactomannan-surveillance-may-be-safely-withdrawn-from-antifungal-management-of-hematology-patients-on-effective-antimold-prophylaxis-a-pilot-single-center-study
#7
R F Duarte, I Sánchez-Ortega, M Arnan, B Patiño, J Ayats, A Sureda, M Cuenca-Estrella
No abstract text is available yet for this article.
October 31, 2016: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/27775697/is-complement-blockade-an-acceptable-therapeutic-strategy-for-hematopoietic-cell-transplant-associated-thrombotic-microangiopathy
#8
P Dhakal, V R Bhatt
Diagnosis and management of hematopoietic cell transplant-associated thrombotic microangiopathy (TA-TMA) are very complex and controversial, given multiple ongoing issues and comorbidities in sick transplant recipients. Complement activation via classic and alternative pathways is emerging as a potential pathogenetic mechanism in the development of TA-TMA. Complement-centric diagnostic strategy using functional and genetic tests may possibly support diagnosis, enhance molecular understanding and direct drug development...
October 24, 2016: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/27751781/epico-3-0-empirical-antifungal-therapy-in-critically-ill-hematology-patients
#9
Pedro Llinares, Isabel Ruiz, Rafael Zaragoza, Ricard Ferrer, Alejandro H Rodríguez, Emilio Maseda, Santiago Grau
BACKGROUND: Although in the past decade the management of invasive fungal infections has improved, a number of controversies persist regarding empirical antifungal treatment in critically-ill hematology patients. AIMS: To identify key clinical knowledge to elaborate a set of recommendations, with a high level of consensus, necessary for the approach to fungal infections in critically-ill hematology patients. METHODS: A Spanish prospective questionnaire, which measures consensus through the Delphi technique, was anonymously answered and e-mailed by 30 multidisciplinary national experts, all specialists in fungal invasive infections from six scientific national societies; intensivists, anesthesiologists, microbiologists, pharmacologists and specialists in infectious diseases...
October 14, 2016: Revista Iberoamericana de Micología
https://www.readbyqxmd.com/read/27744310/galactomannan-testing-and-aspergillus-pcr-in-same-day-bronchoalveolar-lavage-and-blood-samples-for-diagnosis-of-invasive-aspergillosis
#10
Susanne Eigl, Martin Hoenigl, Birgit Spiess, Sven Heldt, Juergen Prattes, Peter Neumeister, Albert Wolfler, Jasmin Rabensteiner, Florian Prueller, Robert Krause, Mark Reinwald, Holger Flick, Dieter Buchheidt, Tobias Boch
In recent years galactomannan antigen testing (GM) and also Aspergillus PCR have become increasingly important for diagnosis of invasive aspergillosis (IA). Whether or not these tests need to be performed with bronchoalveolar lavage fluid (BALF; i.e., primary site of infection), or testing of blood samples is sufficient, remains, however, a matter of debate. We evaluated the diagnostic performance of GM ELISA, and Aspergillus PCR by using BALF samples and blood samples obtained at the same day from a total of 53 immunocompromised patients (16 with probable/proven IA and 37 with no evidence of IA according to the revised EORTC/MSG criteria; 38 patients with hematological malignancies were prospectively enrolled at the Medical University of Graz, Austria, 15 patients with mixed underlying diseases at the Mannheim University Hospital)...
October 14, 2016: Medical Mycology: Official Publication of the International Society for Human and Animal Mycology
https://www.readbyqxmd.com/read/27743353/compatibility-of-biosimilar-filgrastim-with-cytotoxic-chemotherapy-during-the-treatment-of-malignant-diseases-venice-a-prospective-multicenter-non-interventional-longitudinal-study
#11
Stefan Fruehauf, Burkhard Otremba, Oliver Stötzer, Christine Rudolph
INTRODUCTION: Febrile neutropenia (FN) is a serious and frequent complication of cytotoxic chemotherapy. Biosimilar filgrastim (Nivestim™, Hospira Inc, A Pfizer Company, Lake Forest, IL, USA) is a granulocyte-colony stimulating factor licensed for the treatment of neutropenia and FN induced by myelosuppressive chemotherapy. The primary goal of this VENICE study (ClinicalTrials.gov identifier, NCT01627990) was to observe the tolerability, safety and efficacy of biosimilar filgrastim in patients receiving cancer chemotherapy...
November 2016: Advances in Therapy
https://www.readbyqxmd.com/read/27730741/successful-use-of-oseltamivir-prophylaxis-in-managing-a-nosocomial-outbreak-of-influenza-a-in-a-hematology-and-allogeneic-stem-cell-transplant-unit
#12
Mimi C Yue, Joel T Collins, Elango Subramoniapillai, Glen A Kennedy
AIM: To describe a nosocomial outbreak of H1N1 influenza A in an inpatient hematology and allogeneic stem cell transplant unit and outcomes of universal oseltamivir prophylaxis. METHODS: Medical records of all patients admitted to the unit were reviewed to define the nosocomial outbreak, commencing 1 week prior to the index case until 4 weeks following institution of oseltamivir prophylaxis. Timelines for clinical symptoms, viral spread, management, patient outcomes and follow up testing were constructed...
October 12, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27721666/intermittent-courses-of-corticosteroids-also-present-a-risk-for-pneumocystis-pneumonia-in-non-hiv-patients
#13
Maria L Calero-Bernal, Isabel Martin-Garrido, Mikel Donazar-Ezcurra, Andrew H Limper, Eva M Carmona
Introduction. Pneumocystis pneumonia (PCP) is rising in the non-HIV population and associates with higher morbidity and mortality. The aggressive immunosuppressive regimens, as well as the lack of stablished guidelines for chemoprophylaxis, are likely contributors to this increased incidence. Herein, we have explored the underlying conditions, immunosuppressive therapies, and clinical outcomes of PCP in HIV-negative patients. Methods. Retrospective analysis of PCP in HIV-negative patients at Mayo Clinic from 2006-2010...
2016: Canadian Respiratory Journal: Journal of the Canadian Thoracic Society
https://www.readbyqxmd.com/read/27705929/a-5-day-cytoreductive-chemotherapy-followed-by-haplo-identical-hsct-fa5-bucy-as-a-tumor-ablative-regimen-improved-the-survival-of-patients-with-advanced-hematological-malignancies
#14
Ting Yang, Qiaoxian Lin, Jinhua Ren, Ping Chen, Xiaohong Yuan, Xiaofeng Luo, Tingbo Liu, Jing Zheng, Zhihong Zheng, Xiaoyun Zheng, Xinji Chen, Langhui Zhang, Hao Zheng, Zaisheng Chen, Xueling Hua, Shaohua Le, Jian Li, Zhizhe Chen, Jianda Hu
Haplo-HSCT has been used when HLA-matched siblings are not available. Conditioning regimens aim to reduce tumor burden prior to HSCT and provide sufficient immunoablation. We report the outcome of haplo-HSCT in 63 consecutive patients from 2/2013 to 12/2015 (19 females/44 males) with high-risk or relapsed/refractory hematological malignancies (n=29-AML; 8-sAML; 19-ALL; 5-advanced-MDS; 2-CML-BC). Median age was 20 years (range: 1.1-49). Twenty-one patients achieved remission prior to transplant, while 42 did not...
October 1, 2016: Oncotarget
https://www.readbyqxmd.com/read/27686684/a-case-report-of-unusually-long-lag-time-between-immunotactoid-glomerulopathy-itg-diagnosis-and-diffuse-large-b-cell-lymphoma-dlbcl-development
#15
Aditi Khandelwal, Martina A Trinkaus, Hassan Ghaffar, Serge Jothy, Marc B Goldstein
BACKGROUND: Immunotactoid glomerulopathy (ITG) is a rare cause of proteinuria characterized by organized microtubular deposits in the glomerulus. ITG has been associated with underlying lymphoproliferative disorders and any renal impairment may be reversible with treatment of the concomitant hematologic malignancy. This case is the first reported in literature where diffuse large B cell lymphoma developed two years following the initial ITG diagnosis. CASE PRESENTATION: A 55-year-old woman with a history of well-controlled diabetes mellitus and thalassemia trait presented with proteinuria (830 mg/day) in 2010...
September 29, 2016: BMC Nephrology
https://www.readbyqxmd.com/read/27682882/risk-stratification-for-invasive-fungal-infections-in-patients-with-hematological-malignancies-seifem-recommendations
#16
Livio Pagano, Alessandro Busca, Anna Candoni, Chiara Cattaneo, Simone Cesaro, Rosa Fanci, Gianpaolo Nadali, Leonardo Potenza, Domenico Russo, Mario Tumbarello, Annamaria Nosari, Franco Aversa
Invasive fungal infections (IFIs) are an important cause of morbidity and mortality in immunocompromised patients. Patients with hematological malignancies undergoing conventional chemotherapy, autologous or allogeneic hematopoietic stem cell transplantation are considered at high risk, and Aspergillus spp. represents the most frequently isolated micro-organisms. In the last years, attention has also been focused on other rare molds (e.g., Zygomycetes, Fusarium spp.) responsible for devastating clinical manifestations...
September 17, 2016: Blood Reviews
https://www.readbyqxmd.com/read/27671065/antimold-prophylaxis-may-reduce-the-risk-of-invasive-fusariosis-in-hematologic-patients-with-superficial-skin-lesions-with-positive-culture-for-fusarium
#17
Andrea G Varon, Simone A Nouér, Gloria Barreiros, Beatriz Moritz Trope, Tiyomi Akiti, Marcio Nucci
Hematologic patients with superficial skin lesions on admission growing Fusarium spp. are at a high risk for developing invasive fusariosis during neutropenia. We evaluated the impact of primary prophylaxis with a mold-active azole in preventing invasive fusariosis in these patients. Between August 2008 and December 2014, patients with acute leukemia or aplastic anemia and recipients of hematopoietic cell transplants were screened on admission with dermatologic and direct exams and fungal cultures of superficial skin lesions...
December 2016: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27669175/efficacy-of-prophylactic-antiviral-therapy-and-outcomes-in-hbsag-negative-anti-hbc-positive-patients-receiving-chemotherapy-a-real-life-experience
#18
Nikolaos Papadopoulos, Melanie Deutsch, Spilios Manolakopoulos, Chrysoula Bitsi, Helias Michalakeas, Helias Poulakidas, Eftychia Tsironi, Stavroula Giannouli, George V Papatheodoridis, John Koskinas, Dimitrios Pectasides
OBJECTIVE: The aim of this study is to evaluate the outcomes of hepatitis B surface antigen (HBsAg)-negative, anti-HBc-positive patients who received immunosuppressive therapies. PATIENTS AND METHODS: We retrospectively evaluated the medical records of HBsAg-negative, anti-HBc-positive patients with hematological diseases or solid tumors who underwent immunosuppressive therapies and were referred because of positive baseline hepatitis B virus (HBV) serology or HBV reactivation...
January 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27662017/comparison-of-graft-versus-host-disease-free-relapse-free-survival-according-to-a-variety-of-graft-sources-antithymocyte-globulin-and-single-cord-blood-provide-favorable-outcomes-in-some-subgroups
#19
Yoshihiro Inamoto, Fumihiko Kimura, Junya Kanda, Junichi Sugita, Kazuhiro Ikegame, Hideki Nakasone, Yasuhito Nannya, Naoyuki Uchida, Takahiro Fukuda, Kosuke Yoshioka, Yukiyasu Ozawa, Ichiro Kawano, Yoshiko Atsuta, Koji Kato, Tatsuo Ichinohe, Masami Inoue, Takanori Teshima
Graft-versus-host disease-free relapse-free survival, which is defined as the absence of grade III-IV acute graft-versus-host disease, systemically treated chronic graft-versus-host disease, relapse, and death, is a novel, meaningful composite end point for clinical trials. To characterize risk factors and differences in graft-versus-host disease-free relapse-free survival according to a variety of graft sources, we analyzed 23,302 patients with hematologic malignancy that had a first allogeneic transplantation from 2000 through 2013 using the Japanese national transplant registry database...
December 2016: Haematologica
https://www.readbyqxmd.com/read/27648203/antifungal-prophylaxis-in-immunocompromised-patients
#20
REVIEW
Lourdes Vazquez
Invasive fungal infections (IFIs) represent significant complications in patients with hematological malignancies. Chemoprevention of IFIs may be important in this setting, but most antifungal drugs have demonstrated poor efficacy, particularly in the prevention of invasive aspergillosis. Antifungal prophylaxis in hematological patients is currently regarded as the gold standard in situations with a high risk of infection, such as acute leukemia, myelodysplastic syndromes, and autologous or allogeneic hematopoietic stem cell transplantation...
2016: Mediterranean Journal of Hematology and Infectious Diseases
keyword
keyword
105031
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"